Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmed M Musa

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Frontiers in Cellular and Infection Microbiology|June 19, 2018
Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral LeishmaniasisAnke E Kip, Monique Wasunna, Fabiana Alves, et al.
Genes|June 12, 2019
Distribution of Duffy Phenotypes among <i>Plasmodium vivax</i> Infections in SudanMusab M A Albsheer, Kareen Pestana, Safaa Ahmed, et al.
Annals of Saudi Medicine|June 5, 2014
Visceral leishmaniasis-hepatitis B/C coinfections: a rising necessity to triage patients for treatmentAbubakr O A, Mohamed M M, Hatim A A, et al.
BMC Infectious Diseases|December 4, 2014
Insights into the possible role of IFNG and IFNGR1 in Kala-azar and Post Kala-azar Dermal Leishmaniasis in Sudanese patientsMohamed A M Salih, Michaela Fakiola, Mohamed H Abdelraheem, et al.
Plos Neglected Tropical Diseases|November 5, 2010
Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding studyAhmed M Musa, Brima Younis, Ahmed Fadlalla, et al.
Human Vaccines & Immunotherapeutics|August 28, 2012
Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccinesMona E E Elfaki, Eltahir A G Khalil, Anne S De Groot, et al.
Trials|July 2, 2011
Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trialRaymond Omollo, Neal Alexander, Tansy Edwards, et al.
The Journal of Antimicrobial Chemotherapy|September 19, 2023
Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasisLuka Verrest, Ignace C Roseboom, Monique Wasunna, et al.
Plos Neglected Tropical Diseases|April 19, 2024
Leishmania blood parasite dynamics during and after treatment of visceral leishmaniasis in Eastern Africa: A pharmacokinetic-pharmacodynamic modelLuka Verrest, Séverine Monnerat, Ahmed M Musa, et al.
Plos Genetics|May 16, 2007
Y chromosome lineage- and village-specific genes on chromosomes 1p22 and 6q27 control visceral leishmaniasis in SudanE Nancy Miller, Manal Fadl, Hiba S Mohamed, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Frontiers in Cellular and Infection Microbiology|June 19, 2018
Macrophage Activation Marker Neopterin: A Candidate Biomarker for Treatment Response and Relapse in Visceral LeishmaniasisAnke E Kip, Monique Wasunna, Fabiana Alves, et al.
Genes|June 12, 2019
Distribution of Duffy Phenotypes among <i>Plasmodium vivax</i> Infections in SudanMusab M A Albsheer, Kareen Pestana, Safaa Ahmed, et al.
Annals of Saudi Medicine|June 5, 2014
Visceral leishmaniasis-hepatitis B/C coinfections: a rising necessity to triage patients for treatmentAbubakr O A, Mohamed M M, Hatim A A, et al.
BMC Infectious Diseases|December 4, 2014
Insights into the possible role of IFNG and IFNGR1 in Kala-azar and Post Kala-azar Dermal Leishmaniasis in Sudanese patientsMohamed A M Salih, Michaela Fakiola, Mohamed H Abdelraheem, et al.
Plos Neglected Tropical Diseases|November 5, 2010
Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding studyAhmed M Musa, Brima Younis, Ahmed Fadlalla, et al.
Human Vaccines & Immunotherapeutics|August 28, 2012
Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccinesMona E E Elfaki, Eltahir A G Khalil, Anne S De Groot, et al.
Trials|July 2, 2011
Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trialRaymond Omollo, Neal Alexander, Tansy Edwards, et al.
The Journal of Antimicrobial Chemotherapy|September 19, 2023
Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasisLuka Verrest, Ignace C Roseboom, Monique Wasunna, et al.
Plos Neglected Tropical Diseases|April 19, 2024
Leishmania blood parasite dynamics during and after treatment of visceral leishmaniasis in Eastern Africa: A pharmacokinetic-pharmacodynamic modelLuka Verrest, Séverine Monnerat, Ahmed M Musa, et al.
Plos Genetics|May 16, 2007
Y chromosome lineage- and village-specific genes on chromosomes 1p22 and 6q27 control visceral leishmaniasis in SudanE Nancy Miller, Manal Fadl, Hiba S Mohamed, et al.
Pageof 4